Researchers at Johns Hopkins Kimmel Cancer Center developed a prototype for a new cancer immunotherapy that uses engineered T cells to target a genetic alteration common among all cancers.
In two back-to-back, all-day meetings, the FDA Oncologic Drugs Advisory Committee considered four thorny applications that the agency appeared to have been saving up as a result of the pause in activity that followed President Trump’s return to office.
